<DOC>
	<DOCNO>NCT02797795</DOCNO>
	<brief_summary>This study first-in-human , multicenter , open-label , nonrandomized , dose-escalation trial conduct 2 sequential part : - Part A ( Dose Escalation ) subject advanced malignancy - Part B ( Dose Confirmation ) subject tumor type ( ) determine result Part A</brief_summary>
	<brief_title>A Phase 1 , Open-Label , Dose-Escalation Study NEV801 , Administered Patients With Advanced Cancers</brief_title>
	<detailed_description>In Part A , subject treat 30-minute intravenous ( IV ) infusion NEV801 Days 1 , 8 , 15 , 22 continuous 28-day cycle . The start dose NEV801 20 mg/m2/dose , NEV801 dose escalate successive cohort 3 subject per dose level . In Part B , 3 expansion cohort 12 subject , define tumor type , enrol MTD ( i.e. , RP2D ) NEV801 . In part , subject tolerate drug experience progressive disease may continue receive NEV801 discretion Investigator 12 cycle . Subjects tolerate drug experience clinical benefit eligible treatment extension protocol another mean determine Sponsor .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Male female least 18 year age 2 . Willing able provide write informed consent comply requirement study 3 . Pathologically confirm advanced malignancy standard therapy proven provide clinical benefit exist longer effective 4 . Part A : Evaluable disease , measurable either physical examination image accord RECIST v1.1 informative tumor marker ( ) 5 . Part B : Selected tumor type ( ) , determine result Part A 6 . Part B : Measurable disease , use RECIST v1.1 7 . ECOG performance status 0 1 1 . Receipt 5 prior regimen cytotoxic chemotherapy ( unless prior approval grant Sponsor ) 2 . Any chemotherapy , immunomodulatory drug therapy , antineoplastic hormonal therapy , immunosuppressive therapy , corticosteroid &gt; 20 mg/day prednisone equivalent ( unless administer prevent contrast material reaction radiographic procedure ) , growth factor treatment ( e.g. , erythropoietin ) within 14 day first NEV801 dose 3 . Presence acute chronic toxicity prior chemotherapy , exception alopecia , resolve â‰¤ Grade 1 , accord NCI CTCAE v4.03 4 . Radiotherapy within 28 day first NEV801 dose 5 . Use within 7 day first NEV801 dose , anticipate use , agent strong inhibitor CYP3A4 , CYP1A2 CYP2D6 enzymes ( unless approve Sponsor ) see Section 5.6 list strong CYP3A4 , CYP1A2 CYP2D6 inhibitor 6 . Use investigational agent within 28 day first NEV801 dose 7 . Major surgery within 28 day first NEV801 dose 8 . Life expectancy &lt; 12 week 9 . Uncontrolled congestive heart failure ( New York Heart Association Classification 3 4 ) , angina , myocardial infarction , cerebrovascular accident , coronary/peripheral artery bypass graft surgery , transient ischemic attack , pulmonary embolism within 3 month first NEV801 dose 10 . History ongoing cardiac dysrhythmias require treatment , atrial fibrillation grade , persistent prolongation QT correct Fridericia formula ( QTcF ) interval &gt; 450 msec male &gt; 470 msec female 11 . Previous malignancy nonsquamouscell carcinoma skin carcinoma situ uterine cervix ( unless tumor treat curative intent 2 year first NEV801 dose ) 12 . Active bacterial , viral , fungal infection require systemic therapy . 13 . Known HIV infection AIDSrelated illness 14 . Known active viral hepatitis 15 . Presence genetic polymorphism UGT1A1 lead reduce glucuronidation 16 . Pregnant lactate female 17 . Women childbearing potential , unless agree use 2 contraceptive method , opinion Investigator , effective adequate subject 's circumstance study drug 3 month afterward 18 . Men partner woman childbearing potential , unless agree use 2 effective contraceptive method ( i.e. , condom , female partner use oral , injectable , barrier method ) study drug 3 month afterward 19 . Any severe , acute , chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation NEV801 administration ; may interfere informed consent process compliance requirement study ; may interfere interpretation study result , Investigator 's opinion , would make subject inappropriate entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>